Dynavax hepatitis C drug brings antiviral response in early-stage trial

01/26/2010 | Reuters

An early-stage study showed that high doses of Dynavax Technologies' hepatitis C drug reduced the severity of viral infection in patients who also received other antivirals. The treatment, SD-101, outperformed older drugs in stimulating the production of two forms of interferons, which help the immune system fight viruses and other pathogens.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Director of Operations - GBS
Mayo Clinic
Rochester, MN
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Senior Vice President, Clinical Affairs & Strategic Partnerships
America's Health Insurance Plans (AHIP)
Washington, DC